Chronic radiation bowel disease study
Part of Digestive system clinical trials.
This study looks at how different types of chronic radiation enteropathy, a bowel condition caused by radiation therapy, are linked to patient outcomes. It may help doctors better predict how the condition progresses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with chronic radiation enteropathy (a bowel condition caused by radiation treatment).
- You are not currently receiving cancer treatment.
- Your cancer has not returned or spread.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a dietary supplement to help heal damage inside the rectum caused by pelvic radiation therapy. If you have mild to moderate rectal bleeding but no signs of cancer recurrence, you may be able to join.
This trial tests whether a special dietary supplement can help protect the rectum from radiation damage during chemoradiation for locally advanced rectal cancer. If it works, it may reduce painful bowel symptoms like frequent stools and cramping.
This study looks at how a hormone called GLP-2 (which helps protect the gut) changes during radiation therapy to the belly or pelvis, and whether it relates to side effects like radiation enteritis (inflammation of the gut). The goal is to better understand and possibly predict these side effects to improve care.
This trial tests a new stem cell treatment for chronic radiation proctitis, a condition where the rectum is damaged from radiation therapy. The study will see how these cells spread in your body and if they can help heal the damage.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests whether giving an enema (a liquid medicine inserted into the rectum) called Bergmann can help prevent rectal injury caused by radiation therapy in patients with rectal cancer. If you are about to start short-course radiation, this treatment might reduce side effects like pain or bleeding.
Hear when a new Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.